SEC Form 3 · accession 0001104659-15-006140
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Kagan
Director
Period of report
Jul 3, 2014
Accepted (ET)
Feb 3, 2015 · 10:37 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 19,810 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF1 | $11.35 | holding | — | — | — | — | Jan 5, 2025 | Common Stock, par value $0.001 per share | 15,000 | — | D |
Explanation of responses
- F1Options vest as follows: 50% on the date of grant and the remaining 50% vests in equal installments over a 24 month period, subject to accelerated vesting on a change of control.